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Tricuspid regurgitation (TR) is a common acquired valvular heart disease (VHD). TR has 
progressive character and is associated with impaired long-term survival in both symptomatic 
and asymptomatic subjects. Despite this knowledge, the overall number of tricuspid valve 
surgeries is very low worldwide and many patients with clear indications for intervention are 
left untreated. The development of less invasive transcatheter techniques may offer new 
treatment options in this growing population of patients. Out of various percutaneous methods 
proposed, tricuspid edge-to-edge repair has recently gained considerable attention. The article 
summarizes available data regarding this new treatment method. 
 
INTRODUCTION 
Tricuspid regurgitation (TR) is a common acquired valvular heart disease (VHD). Its 
prevalence is rapidly growing with the aging population, as a recent population study indicates 
its prevalence nearly equals that of severe aortic stenosis [1]. In most cases, TR has a functional 
character frequently secondary to left-sided congestive heart failure or VHD and a subsequent 
right ventricular enlargement. In a growing number of patients with preserved right ventricular 
function, an alternative mechanism of TR due to tricuspid annulus dilatation in the setting of 
longstanding atrial fibrillation has been reported [2]. Finally, secondary functional TR develops 
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in a large portion of patients previously operated on for mitral or aortic valve disease, causing 
the recurrence of heart failure symptoms [3].  
Tricuspid regurgitation is a progressive disease that is associated with impaired long-term 
survival in both symptomatic and asymptomatic subjects [4, 5]. The presence of severe TR is 
associated with a nearly 2-fold increase in the mortality rate of heart failure patients. The 
reported overall 10-year survival rate is lower than 40% [6]. Moreover, a linear correlation 
between regurgitation severity, defined as effective regurgitant orifice area, and mortality was 
recently been reported [7].  
The presence of a moderate or worse TR is a well-established risk factor and affects the long-
term survival in patients undergoing both surgical and percutaneous procedures for left-sided 
VHD [8]. TR is not only a marker of disease severity but also a potential target for therapeutic 
intervention and thus current guidelines advocate using a liberal approach for a concomitant 
tricuspid valve (TV) repair in patients undergoing surgical treatment of left-sided VHD. 
Despite this knowledge, the overall number of tricuspid valve surgeries is very low worldwide 
and many patients with clear indications for intervention are left untreated. The development 
of less invasive transcatheter techniques may offer new treatment options in this growing 
population of patients. Out of various percutaneous methods proposed, tricuspid edge-to-edge 
repair has recently gained considerable attention.  
 
EDGE-TO-EDGE REPAIR FOR TRICUSPID REGURGITATION 
During the last decade, percutaneous edge-to-edge repair has become a well-established 
treatment method in patients with mitral valve insufficiency. In approximately 25%–30% of 
patients referred for this therapy, concomitant severe TR is also documented. The treatment of 
mitral regurgitation alone led to a reduction of TR grade in only 30%–40% of cases [9], 
therefore the development of edge-to-edge tricuspid repair was a natural next step in the therapy 
of patients with concomitant mitral and tricuspid disease.  
The first percutaneous tricuspid edge-to-edge repair was performed under the off-label use of 
the MitraClip system (Abbott Vascular, Santa Clara, CA, USA) via the jugular vein in 2015, 
followed shortly by successful transfemoral procedures [10]. An early feasibility study that was 
conducted in 64 patients with both isolated TR or concomitant mitral and tricuspid insufficiency 
and deemed unsuitable for surgery, showed high periprocedural success with 97% tricuspid clip 
implantation rate and 91% having at least one grade reduction in TR severity. The therapy 
proved to be safe with no periprocedural complications and effective in terms of New York 
Heart Association (NYHA) class and exercise tolerance improvements [11]. 
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Further studies have indicated a durable reduction to a moderate or less TR at 12-month follow-
up. This was observed in 72% of patients and accompanied by a 22% reduction in heart failure 
hospitalizations and an improvement of a 1-year survival from 60% to 79% when compared to 
patients who failed a TR repair attempt [12]. Furthermore, in the absence of randomized data, 
a recent retrospective cohort study showed that the tricuspid edge-to-edge repair with the 
MitraClip NT system in addition to optimal medical therapy in patients with severe TR 
significantly reduced mortality (24.9% vs 53.1%; median 14-month follow-up) when compared 
to the medical therapy only [13]. 
 
POSSIBLE CLINICAL INDICATIONS FOR PERCUTANEOUS EDGE-TO-EDGE 
THERAPY FOR TRICUSPID REGURGITATION 
Recently published European Society of Cardiology guidelines for the management of valvular 
heart disease for the first time introduced the possibility of percutaneous intervention in patients 
with TR. According to the document, it may be considered by local Heart Team at experienced 
centers in symptomatic, inoperable and anatomically eligible patients. However, because of the 
data paucity, no specific recommendations regarding different clinical situations are given [14]. 
In patients with TR, we usually deal with two clinical scenarios: coexistence of tricuspid and 
mitral regurgitation in a patient scheduled for edge-to-edge mitral valve repair or a patient with 
isolated TR. Due to the lack of exact indications concerning percutaneous treatment, guidelines 
on surgical treatment might prove to be helpful in everyday clinical decision making.  
In the first scenario, according to the current guidelines, patients scheduled for left-sided valve 
surgery should undergo concurrent tricuspid repair if a severe TR is present.  
This strategy should also be considered in subjects without significant TR but with a dilated 
tricuspid annulus (i.e., ≥40 mm or >21 mm/m² by 2D echocardiography) or with current or 
previous symptoms and signs of right-sided heart failure as in such cases the probability of TR 
progression during follow-up is substantial. This approach does not add risk to the index 
surgical intervention while reducing the need for higher risk re-intervention [15]. As previously 
said, up to 30% of patients treated with MitraClip for magnetic resonance (MR) have significant 
TR. The presence of TR independently worsens prognosis after isolated mitral edge-to-edge 
repair. There is only a moderate probability that successful MR repair will improve TR. 
However, it is possible to correct TR simultaneously by the off-label use of the same MitraClip 
device, provided the tricuspid valve anatomy is suitable and echo visualization is of good 
quality. The results of several registries suggest that this strategy reduces heart failure 
symptoms and the total dose of diuretics. Recently the pooled data of patients with significant 
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MR and TR from TRAMI and TriValve registries were retrospectively analyzed. Subjects 
enrolled in TriValve underwent concurrent mitral and tricuspid treatment while patients 
observed in the TRAMI registry only had an isolated mitral intervention performed. At one-
year follow-up, concurrent TR treatment was independently associated with lower mortality 
(16.4% vs 34%; P = 0.035) [16, 17]. Nevertheless, further controlled randomized studies are 
needed to confirm these promising observations. 
According to available data, in our opinion, concurrent edge-to-edge correction of TR in 
patients scheduled for MR treatment may be considered in patients with good 
echocardiographic visualization of the tricuspid valve, favorable valve anatomy, and: 
— moderate-to-severe or greater TR regardless of symptoms of right-sided heart failure; 
— moderate TR in patients with current or previous symptoms or signs of right-sided heart 
failure. 
Currently, we do not recommend edge-to-edge tricuspid repair in patients with less than 
moderate TR and annular dilatation. These patients should be closely observed and if the TR 
progresses possibly scheduled for a staged isolated TR correction with a dedicated device.  
In the case of patients with isolated TR, open-heart surgery is associated with a high 
periprocedural mortality risk that reaches 10%–25% in severely symptomatic patients [18]. 
This may be the result of unfavorable baseline clinical characteristics of the patients, who often 
suffer from secondary liver and/or renal failure. According to the current guidelines, surgery 
should be considered in patients with isolated significant TR with signs and symptoms of right-
sided heart failure. The procedure should be optimally performed before the onset of right 
ventricular dysfunction or end-organ failure. The surgery might be also be considered in 
patients with prior left-sided valve surgery and isolated TR but without right ventricular 
dysfunction or severe pulmonary hypertension. However, given the high surgical risk, many 
symptomatic patients with severe TR are denied surgery. Percutaneous TR treatment with an 
edge-to-edge technique may be a valid option for this population.  
In our opinion, in case of isolated TR, percutaneous edge-to-edge repair might be considered 
by the Heart Team in symptomatic, high surgical risk patients with moderate to severe TR, 
favorable valve anatomy, good echocardiographic valve visualization, and without significant 
pulmonary hypertension. The expected life expectancy should exceed 12 months to avoid 
futility. 
 
ECHOCARDIOGRAPHIC ASSESSMENT OF THE TRICUSPID VALVE IN THE 
CONTEXT OF INTERVENTION 
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When compared to other valves, the tricuspid valve has complex and variable anatomy. It is 
usually composed of three separate leaflets: an anterior and septal leaflet in addition to a smaller 
posterior leaflet, however accessory leaflets can be also present. Only the septal portion of the 
annulus is relatively solid, while the remaining part is prone to dilatation, which is the typical 
reason for functional TR. The regurgitant orifice can be central, but in most cases, it has a 
complex shape due to pericommissural leakage. Primary and secondary chords connected to 
small and variable papillary muscles or directly to the myocardium can cause leaflet restriction 
— another mechanism of TR.  
Both the thin leaflets and the subvalvular apparatus are poorly echogenic. The valve is located 
off axis from the esophagus (Figure 1). That is why, when compared to the mitral, the tricuspid 
valve is a much more demanding imaging target. Although multiple transthoracic (TTE) and 
transesophageal (TEE) 2D views, accompanied by biplane and 3D imaging can overcome this 
problem, approx. 20% of patients obtaining sufficient imaging quality may not be possible. 
Even for experienced echocardiographers, specific training is needed to distinguish the three 
leaflets and assess the valve’s repairability. It is even more demanding to select the implantation 
target, provide navigation images, and check the coaxiality/perpendicularity of the clip prior to 
implantation. Ventricular pacing leads are frequently present in TR patients and require special 
attention regarding their influence on the mobility of the leaflets. The presence of the pacemaker 
leads, especially when colliding with the valve leaflets, decreases the chances of a successful 
procedure. Commissural rather than central position can be accepted in patients referred for 
edge-to-edge repair.  
Detailed TTE evaluation requires TV parasternal long- and short-axis views, an apical 4-
chamber view with anterior and posterior modifications, and substernal views to distinguish the 
TV leaflets (Figure 2). The mechanism and localization of the main TR orifice, as well as TR 
severity, should be assessed (Table 1). In candidates for edge-to-edge intervention, TEE is 
needed to make sure the valve is sufficiently visible (when the patient is positioned on their 
back) and to pre-plan the valve clipping prior to qualification for the procedure. 
Understanding the orientation of the specific views and meaning of the anatomical landmarks 
are helpful both in TTE and TEE in distinguishing the leaflets and to localize the commissures 
(Figure 2). It can be practiced using a simulator — the most important images are explained in 
Figures 3–6. The antero-septal commissure is located close to the aortic valve (next to N-R 
commissure) and the postero-septal commissure lays between the coronary sinus and inferior 
vena cava (Figure 1). Due to anatomical limitations, 2D images cannot be fully coaxial with 
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the trajectory of the device. If the imaging quality is sufficient it can be solved by multiplanar 
live 3D imaging.  
 
ECHOCARDIOGRAPHIC CRITERIA OF PATIENT SELECTION 
Two systems are currently approved (CE mark) for the edge-to-edge tricuspid valve repair in 
Europe — TriClip and Pascal. According to the Instructions For Use, the TriClip device is 
indicated for patients with severe TR with valve anatomic coaptation gaps of ≤1.0 cm, are at 
high risk for tricuspid valve surgery, do not have severe mitral regurgitation or pulmonary 
hypertension (systolic pulmonary artery pressure >60 mm Hg), and are symptomatic despite 
medical therapy [22]. Contraindications include rheumatic tricuspid valve disease, active 
endocarditis, and thrombi both intracardiac and located in vena cava or femoral veins. The 
device is not approved for TR associated with congenital tricuspid valve lesions. The required 
minimum leaflet insertion (6 mm for smaller and 9 mm for larger devices) defines minimum 
mobile leaflet length as being 9 mm and 12 mm for NT and XT clips respectively. As leaflet 
grasping may potentially cause valvular stenosis a pre-implant mean pressure gradient ≤3 mm 
Hg is recommended (mean pressure gradient of ≥5 mm Hg should be considered a significant 
risk factor for creating tricuspid valve stenosis).  
According to the manufacturer’s instructions, the Edwards PASCAL transcatheter valve repair 
system is indicated for the percutaneous reconstruction of an insufficient or tricuspid valve 
through tissue approximation [23]. Echocardiographic contraindications include the inability to 
complete the screening with TEE and the presence of an intracardiac mass, thrombus, or 
vegetation. The operator should also consider the following anatomic patient characteristics: 
non-degenerative tricuspid valve disease, evidence of moderate to severe calcification in the 
grasping area, severe calcification in the annulus or subvalvular apparatus, presence of 
significant cleft or perforation in the grasping area, as well as leaflet mobility length <8 mm.  
The optimal clinical echocardiographic criteria for percutaneous tricuspid edge-to-edge valve 
repair are still evolving. Clinical practice guidelines on the management of valvular heart 
disease provide no formal indications in the selection of patients for percutaneous edge-to-edge 
tricuspid valve repair.  
Baseline right ventricular (RV) size and function, as well as estimates of systolic pulmonary 
artery pressure, did not predict clinical outcomes after transcatheter tricuspid valve repair in a 
substudy of the TriValve Registry [24]. Nevertheless coaptation gap (≤7 mm), central or 
anteroseptal jet location, and tethering height (≤1 cm) determined procedural success, which 
was associated with improved survival [25]. Importantly, as per current clinical practice, 
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percutaneous tricuspid edge-to-edge valve repair is performed not only with torrential (5+) and 
severe (4+) but also with moderate-to-severe (3+) TR (45% in a recent report from the TriValve 
Registry) [26]. 
 
In summary: echocardiographic criteria should include:  
• ≥ moderate-to-severe TR; 
• ≤7 (10) mm coaptation gap; 
• ≥7 (8) mm leaflet length; 
• ≤10 mm tethering height; 
• ≤3 (5) mm Hg mean tricuspid pressure gradient. 
 
Echocardiography should exclude: 
• Technically inadequate examinations; 
• Rheumatic/congenital etiology; 
• Active endocarditis; 
• Intracardiac thrombi; 
• Significant leaflet and annular calcifications. 
 
ECHOCARDIOGRAPHIC INTRAOPERATIVE GUIDANCE DURING THE 
TRICUSPID TRANSCATHETER EDGE-TO-EDGE REPAIR 
Phase 1. Navigating to the Tricuspid Valve  
During the tricuspid transcatheter edge-to-edge repair the steerable guide catheter (SGC) is 
introduced into the inferior vena cava to the right atrium (RA) using a modified bi-caval view 
(90–110º). After losing contact with the interatrial septum, in the middle of the right atrium, the 
clip delivery system (CDS) should be gradually pushed out from the SGC. The next step is to 
flex the CDS moving the tip of the system proximally to the tricuspid valve annulus. This step 
of the procedure is guided in multi-plane 2D-TEE or real-time 3D echocardiography 
(RT3DTEE, zoom acquired from 90–110º). These views allow one to follow the tip of the 
system in the right atrium. 
 
Phase 2. Navigating to the Implantation Zone 
Navigation to the area of implantation depends on the coaptation line which is the target of the 
procedure: antero-septal and/or postero-septal. The following steps are used for setting the 
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device over the chosen area: the basal view used for the navigation to the coaptation line antero-
septal/postero-septal is the Right Ventricle Outflow Tract (RVOT) View (60–100º) obtained 
from the high/mid esophagus with the device placed medially, close to the aortic valve (AV). 
In the same reference plane, if the coaptation line postero-septal is chosen as the implantation 
target, the device should be moved laterally to the wall of the RA/RV. The use of bi-plane TEE 
helps with positional assessment in the medio-lateral axis. The position of the device is easy to 
assess when RT3DTEE is used. The RT3DTEE Zoom volume dataset is acquired from a mid-
esophageal 4 chamber view (0–20º or 160–180º). The volume should include anatomical 
landmarks: aortic valve (non-coronary sinus), intra-atrial septum, right atrial appendage, and 
superior vena cava. 
 
Phase 3. Implantation 
After confirmation of the device position over the desired implantation area, the 
perpendicularity of the clip to the coaptation line should be assessed. When the device is close 
to the leaflets, the arms of the clip and coaptation line can be seen using the trans-gastric short-
axis view (20–50º). In the in the latter view, the parallax artifact can interfere with the proper 
perpendicularity adjustment. When perpendicularity is confirmed, the clip should be closed 
again. majority of cases, a similar view can be acquired from RT3DTEE zoom as described 
above. It should be mentioned that 
Under constant monitoring in several views, the device should be placed in the right ventricle 
just below the tricuspid leaflets to avoid entrapment in the subvalvular apparatus. This part of 
the procedure can be monitored using the trans-gastric long-axis view. However, the mid-
esophageal 4 chamber view (0–20º or 160–180º) or bi-plane echocardiography based on the 
RVOT view (reference plane 60–100º) can be also used. The latter is very helpful in cases with 
difficult anatomy or planned postero-septal implantation.  
The perpendicularity to the coaptation line should be confirmed when the device is under the 
leaflets. This can be assessed using the trans-gastric short-axis view or mid-esophageal 
RT3DTEE zoom. Implantation in the antero-septal position can be monitored from the mid-
esophageal 4 chamber view (0–20º or alternate 160–180º). During PS position implantation, 
monitoring from the deep-esophageal 4 chamber view (with coronary sinus in sight, 0–20° or 
alternate 160–180°) might be used. However, in cases of unfavorable anatomy, the RVOT bi-
plane view (as the reference plane) may be helpful to monitor the grasping of the leaflets and 
the closing of the device.  
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Phase 4. Confirmation of proper implantation. 
Post implantation evaluation includes a leaflet insertion assessment. The remaining part of a 
leaflet (distance between the device and annulus) should be measured using the 
echocardiographic view used for implantation monitoring. Following the proper implantation, 
using the transgastric short-axis view the valve should become double-orifice if one clip was 
implanted, or tri-orifice if 2 clips were used. The reduction in TR is checked by color Doppler 
in the high/mid esophageal 2D RVOT view, bi-plane view, or using RT3DTEE. The trans-
gastric long axis view can also be useful in measuring TR reduction. Finally, using a continuous 
wave Doppler, a measurement of the mean gradient through the tricuspid valve should be 
obtained, which should not exceed 5 mm Hg. In some cases, additional measurement during 
the transthoracic examination might be helpful to rule out the possibility of tricuspid stenosis.  
 
TRICUSPID REPAIR WITH THE MITRACLIP SYSTEM  
Most of the percutaneous tricuspid repair procedures reported to date have been performed with 
the MitraClip system. This device has not been approved for the treatment of TR and therefore, 
its use is considered off-label and should be limited to investigational purposes or 
compassionate procedures. Since the system was developed for the treatment of mitral valve 
dysfunction, use in the right atrium causes it to lose much of its steerability and requires 
different handling. There are several techniques described, the following, most often used in 
our practice is one of the possible options.  
Proper TEE imaging with clear visualization of the right atrium, tricuspid valve, and its leaflets, 
especially at the site of planned clip implantation is the most important element of the 
procedure. Fluoroscopic guidance requiring an RAO 30° view played an additional role in most 
cases. Because of the reimbursement restrictions, all of the TR repairs in our practice were 
combined mitral tricuspid interventions. In this setting, the tricuspid repair starts after the 
successful completion of the mitral procedure, if the TEE shows a persistent TR jet. The 
procedural steps are as follows: 
• after the addition of “minus” on an SGC +/– knob the straightened system is slowly 
removed from the intra-atrial septum (bicaval view or right atrium 3D view) (Figure 
7A); 
• CDS is inserted into the SGC in a “mis-key” manner by turning the CDS 90° 
counterclockwise from the “blue-to-blue” position; 
• CDS is then advanced to the end of the SGC under fluoroscopic guidance (bicaval view 
or right atrium 3D view) (Figure 7B); 
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• while the end of the clip is kept in the same position the SGC is withdrawn to obtain 
straddling (bicaval view or right atrium 3D view) (Figure 7C); 
• SGC is rotated counter-clockwise to point the clip at the TV; 
• on CDS A/P knob “P” is added to steer down the tip of the clip to the TV (right atrium 
3D view) (Figure 7D). 
 
The main regurgitation jet should be identified using the short axis trans-gastric (TG-SAX) and 
3D view. The tip of the clip should be pointed at the desired position using the basic SGC 
maneuvers presented in Figure 8. In the majority of cases, the clip is placed between the septal 
and anterior leaflets, or less frequently between septal and posterior leaflets. Once in position, 
the clip is opened and the perpendicularity of the arms to the coaptation line is adjusted (TG-
SAX, 3D) (Figure 9). After insertion of the system into the right ventricle grasping of a leaflet 
can be attempted using the mid-esophageal views (Figure 10). The grasping can be confirmed 
by direct visualization of the leaflet insertion in the mid-esophageal views, by the reduction of 
regurgitation jet, and by leaflet immobilization visible in the TG-SAX view (Figure 11). 
Procedural success is defined as at least one grade reduction in TR severity and lack of a TV 
mean gradient of more than 3 mm Hg.  
The MitraClip system’s off-label use for this indication has several technical limitations which 
might hamper effective TV repair. In some patients, insufficient space between the inferior vena 
cava and the TV might result in low positioning of the device with the clip below the TV plane 
despite full CDS handle retraction. This might prevent successful grasping and result in clip 
entrapment in the right ventricle with an inability to move it into the right atrium. What more, 
the unfavorable orientation of the inferior vena cava and the plane of the valve might cause a 
phenomenon known as “septal hugging” in which the path of the device is not perpendicular to 
the TV plane (Figure 12). These issues have mostly been resolved by the redesigned shape and 
additional steering options of the TriClip, a percutaneous system developed for the treatment 
of TR.  
 
THE TRICLIP SYSTEM 
The TriClip device is a first-in-class transcatheter edge-to-edge repair system dedicated for 
minimally invasive, percutaneous treatment of TR. The TriClip system evolved from the 
MitraClip NTR platform, which is commonly and successfully used not only for mitral valve 
repair but also for TR treatment [27]. Both MitraClip and TriClip systems consist of a SGC and 
CDS with attached cobalt-chromium clips available in two sizes NT and XT (implant arm 
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length 9 and 12 mm respectively). When compared to the MitraClip, the SGC of the TriClip 
has two knobs (S/L and +/–) and CDS one knob (F/E) for the multi-directional steering 
maneuvers and deflection of the system. Modification of the MitraClip system was crucial to 
overcoming the so-called septal huger phenomenon, defined as the tendency to self-position the 
delivery catheter towards the septal leaflet, but also for precise control of perpendicularity and 
height adjustments. 
The efficacy and safety of the TriClip system were established in the TRILUMINATE trial, 
which was a prospective, single-arm, feasibility study conducted at 21 sites in Europe and the 
USA. A total of 85 symptomatic patients with moderate or greater TR underwent a successful 
procedure (100% implant success rate) [28]. On average 2.2 TriClips were implanted, with a 
mean procedure time of 153 minutes. In the majority of cases (77%), the clips were located in 
the antero-septal commissure. The primary efficacy endpoint, defined as a reduction of TR 
severity by at least one grade at 30 days, was met in 86% of patients. At 1 year, a reduction in 
TR was sustained with 71% of the cases being classified as moderate or less TR, especially 
when compared with 8% at baseline (P <0.0001). Echocardiographic assessment performed by 
core lab revealed significant positive right heart remodeling in terms of reduction of right 
ventricular end-diastolic diameter (5.3 vs 4.8 cm; P <0.0001), decrease in right atrial volume 
(129 vs 116 ml; P = 0.0166), and TAPSE improvement (1.44 vs 1.59 cm; P = 0.0002). Patients 
treated with the TriClip device experienced a significant clinical improvement in NYHA 
functional class (percentage of patients with NYHA class I/II 31% vs 83%; P < 0.0001) and 
exercise capacity (6-minute walk test increased from 272.3 to 303.2 meters; P = 0.0023). The 
edge-to-edge therapy was also associated with substantial quality-of-life improvements and 
reduction in hospitalizations. The annual hospitalization rate decreased by 40% when compared 
to one year before the procedure (P = 0.003). 
These results were achieved with few safety concerns such as major bleeding observed in 10 
patients, 5 cases of single leaflet device attachment, and 4 cases with tricuspid valve mean 
gradient equal or greater than 5 mm Hg. The occurrence of major adverse events through 1 year 
was also low with a total number of 6 events including 4 cases of cardiovascular death. Safety 
and effectiveness of the TriClip procedure are currently under investigation in the pivotal trial 
TRILUMINATE (Clinical TRIal to EvaLUate Cardiovascular OutcoMes IN Patients 
TreATEd With the Tricuspid Valve Repair System), which is a prospective, randomized study 
comparing the tricuspid valve edge-to-edge repair system (on top of medical therapy) to 
pharmacotherapy only in patients with severe, symptomatic TR [29]. 
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TRICUSPID REPAIR WITH THE PASCAL SYSTEM  
The PASCAL transcatheter valve repair system (Edwards Lifesciences, Irvine, CA, USA) is a 
leaflet repair therapy initially designed for the treatment of MR which shares the concept of 
edge-to-edge coaptation enhancement [30, 31]. Technical characteristic of both delivery 
systems and clipping devices appears to make it a useful tool in the treatment of TR. It uses a 
pair of clasps and paddles designed to plicate valve leaflets and facilitate coaptation. The broad 
contoured paddles are designed to maximize leaflet coaptation and minimize stress 
concentration on the native leaflets. An anatomic spacer is used to fill the regurgitant orifice 
between the native valve leaflets to prevent backflow, further reducing regurgitant flow. The 
clasps are adjustable which aids in the successful positioning of the leaflets. The clasps can be 
operated either simultaneously or independently to facilitate optimized leaflet capture in cases 
with complex anatomy. The delivery system consists of a 22-F guide sheath, with 3 independent 
catheters that facilitate maneuvering in 3 different planes and stabilizers that lock catheter 
handles in place. The PASCAL repair system implant can be elongated within the subvalvular 
anatomy to substantially decrease the implant profile for an atraumatic repositioning if deemed 
necessary. 
The CLASP study (Edwards PASCAL Transcatheter Mitral Valve Repair System Study) was 
designed to assess the clinical benefit of PASCAL edge-to-edge mitral intervention. Results at 
1-year follow-up in functional mitral regurgitation and degenerative mitral regurgitation were 
recently published [32]. Based on the convincingly positive results of this study, it was 
concluded that the PASCAL transcatheter valve repair system demonstrated a low complication 
rate, high survival rate, and a sustained MR reduction resulting in significant improvements in 
functional status and quality of life at 1 year.  
Results of an observational first-in-human assessment of feasibility and safety of the PASCAL 
transcatheter valve repair system and its impact on short-term clinical outcomes in patients with 
severe TR were encouraging [33]. Twenty-eight patients with severe TR were treated with the 
PASCAL system in a compassionate use intervention at 6 sites. All patients had heart failure 
due to severe TR and were deemed to be high surgical risk by local heart teams. The primary 
outcome was procedural success, defined as the implantation of at least 1 device with post-
procedural TR grade ≤2+, without mortality or conversion to surgery. TR etiology was 
functional in 92% of patients, with a mean tricuspid annular diameter of 49.5 ± 6 mm and a 
mean coaptation gap of 6.9 ± 3 mm. Procedural success was 86%, with 1.4 ± 0.6 devices 
implanted per patient. There were no intraprocedural complications. At 30-day follow-up, 
mortality was 7.1%, 88% of patients were in NYHA functional class I or II, and 85% had a TR 
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grade of ≤2+. There were 2 single-leaflet device attachments, which were managed 
conservatively. The six-minute walk distance improved from 240 m (interquartile range: 172 
to 337 m) to 335 m (interquartile range: 251 to 385 m) (P <0.001). This first-in-human 
experience evaluating transcatheter tricuspid repair with the PASCAL system demonstrated 
high procedural success, acceptable safety, and significant clinical improvement. Efficacy and 
safety of PASCAL therapy in TR patients is further studied in an ongoing CLASP TR Early 
Feasibility Study. Of the 34 patients enrolled in this study, the mean age was 76 years, 53% 
were women, the mean Society of Thoracic Surgeons score was 7.3%, 88% had atrial 
fibrillation/flutter, 97% had severe or greater TR, and 79% had NYHA functional class III/IV 
symptoms. Twenty-nine patients (85%) received implants. Tricuspid regurgitation severity 
reduction of at least 1 grade at 30 days was achieved in 85% of them, with 52% with moderate 
or less TR (P <0.001). The MAE rate was 5.9% and none of the patients experienced 
cardiovascular mortality, stroke, myocardial infarction, renal complication, or reintervention. 
Eighty-nine percent of patients improved to NYHA functional class I/II (P <0.001), improved 
their mean 6-min walk distance by 71 m (P <0.001), and improved the mean Kansas City 
Cardiomyopathy Questionnaire score by 15 points (P <0.001). Investigators concluded that in 
this early experience, the repair system performed as intended, with substantial TR reduction, 
a low adverse events rate, no mortality or reintervention, and significant improvements in 
functional status, exercise capacity, and quality of life [34]. 
 
SUMMARY 
The approach to the management of valvular heart diseases was completely transformed by the 
advent of transcatheter valvular interventions. The use of transcatheter valve therapies allowed 
an expansion of indications to patients previously deemed inoperable. The TR was for a long 
time undertreated, despite its adverse impact on clinical outcomes, including mortality and heart 
failure, as well as associated poor quality of life. The contemporary TR treatment was redefined 
by several important discoveries. Since the first procedure of TR edge-to-edge-repair by 
Nickenig and colleagues, there has been growing evidence from registries (TriValve and others) 
and more recently from prospective clinical trials (Triluminate) that edge-to-edge repair using 
the MitraClip or more recently the TriClip provides a safe and effective treatment, with over 
80% of patients having a significant reduction of TR to moderate or less postoperatively which 
is sustained above 70% at one year. It also leads to a reduction of rehospitalizations and 
improvement in symptoms [26]. Importantly, several prognostic factors related to the anatomy 
of the TV, clinical status (frailty, short life expectancy, severe RV failure, irreversible 
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pulmonary hypertension) were identified. There is also a trend towards improved survival in 
patients undergoing transcatheter tricuspid repair than those treated conservatively. These 
studies have helped identify the patients in whom the therapy is unlikely to produce durable 
improvements and who should not be treated with a transcatheter repair. The technical 
feasibility of the procedure will surely evolve as the operators gain clinical experience. This 
will lead to a higher rate of acceptance for the procedure as well as technical success. In 
addition, multiple new technologies based on transcatheter annuloplasty, implantation of valves 
in caval veins, as well as dedicated tricuspid bioprosthetic valves mounted on self-expandable 
stents were designed and are currently undergoing clinical evaluation.  
From the Polish perspective, it is important to share our initial experience with heart valve 
centers experienced with mitral and tricuspid procedures, train the operators and 
echocardiographers to build up the referral network, and follow-up patients within the registry. 
It seems that at least three groups of patients are likely to be discussed by Heart Teams: 
secondary TR coexisting with significant MR planned for one step mitral and tricuspid clipping, 
patients after left-sided valve surgery and significant TR, and patients with isolated TR. Last, 
but not least it is important to secure the funding for these procedures which are currently not 
reimbursed. The current edition of the Valve-for-Life Initiative by the EAPCI and European 
Society of Cardiology in Poland should be especially focused on these unmet clinical needs.  
In summary, the transcatheter tricuspid edge-to-edge repair seems to be a safe and possibly 
effective treatment for patients with heart failure and significant TR, leading to the reduction 
of its severity and clinical improvement in a significant number of patients. This field is rapidly 
expanding and Poland joined the group of countries which can offer patients access to this 
innovative and effective therapy.  
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Table 1. Echocardiographic criteria of TR severity table modified, based on [19–21]. The most 
important parameters are marked in bold 









Paradoxical/volume overload pattern 
















CW signal of TR jet Faint/parabol





Dense, triangular, early peaking (peak 
<2 ms in very severe TR) 
IVC diameter normal 21–25 mm >25 mm 
Semi-quantitative 
Color flow jet area 
(central jet) 
<5 cm2 5–10 cm2 >10 cm2 
Color jet area/RA 
area 
10%–20% 10%–33% >33% 
Vena contracta 
(Nyquist limit 50–60 
cm/s) 
<3 mm <6 mm 7–13 mm 14–20 mm ≥21 mm 
PISA 
(Nyquist limit 28 
cm/s) 
≤5 mm 6–9 mm >9 mm 




Systolic flow reversal 
Tricuspid inflow E <1 m/s  
or A wave 
dominant 
Variable E wave >1m/s 
Quantitative      
EROA (by PISA) <20 mm2 20–39 mm2 40–59 mm2 60–79 mm2 ≥80 mm2 
EROA (by 3D vena 
contracta) 






<30 ml 30–45 ml ≥45 ml 






Abbreviations: CW, continuous wave; EROA, effective regurgitant orifice area; IVC, inferior 
vena cava; NA, not applicable; PISA, proximal isovelocity surface area; RA, right atrium; RV, 




Figure 1. Anatomical specimen of the heart without atrial walls (A). Esophagus is located 
above the mitral valve, and the TV has to be imaged in an oblique way. Corresponding 3D view 
of the TV. The commissures are marked with arrows. Note anatomical landmarks: Ao, IAS, 
CS, IVC. Position of the AVN is also shown. 
Abbreviations: ant, anterior; Ao, aorta; AVN, atrioventricular node; CS, coronary sinus; IAS, 
interatrial septum; IVC, inferior vena cava; LAA, left atrial appendage; post, posterior; RAA, 




Figure 2. Main TTE views modified to differentiate the tricuspid valve leaflets. Left panel: 
Parasternal long axis view (A) modified to visualize the anterior and septal (B) or anterior and 
posterior leaflets (C). Right panel: 4-chamber view tilted anteriorly (D) and posteriorly (E). 
Note the landmarks — CS, IVC with EV and LVOT. 
Abbreviations: EV, Eustachian valve; LVOT, left ventricle outflow tract; TTE, transthoracic 
echocardiography; other see Figure 1 
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Figure 3. Simulation of the mid-esophageal 0° 4-chamber modified by retroflexing (A) or 
anteflexing the probe (B) to differentiate the posterior from the anterior leaflet, both coapting 
with the septal leaflet. Similar views can be obtained by inserting or pulling back the probe or 
by tilting the TTE 4-chamber plane (Figure 2D and 2E). 




Figure 4. Simulation of the mid-esophageal xPlane study. Upper images show 90° view with 
xPlane cursor positioned on the posterior leaflet (A), the orthogonal plane shows septal and 
posterior leaflets (B). The model (C) explains orientation of the imaging planes marked with 
red-blue and yellow-green edges. Respectively, lower images explain the effect of moving the 
xPlane cursor to the right towards the anterior leaflet (D–F) 
Abbreviations: LA, left atrial; LV, left ventricular; RA, right atrial; RV, right ventricular; other 






Figure 5. Simulation of the shallow-transgastric xPlane study. The probe is flexed anteriorly 
and towards the right. Left panel shows the 0° view with xPlane cursor positioned on the septal 
and anterior leaflets (A), while the orthogonal plane shows short axis of the valve with all three 
leaflets (B). The model (C) explains orientation of the imaging planes marked with red-blue 
and yellow-green edges. The lower panel (D–F) shows the opposite way to obtain similar 
views. Steering the xPlane cursor on the short image of the valve (D) can orient the long axis 
plane (E) on the desired leaflets. 
Abbreviations: see Figure 1 and 4  
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Figure 6. Simulation of the deep-transgastric xPlane study. The probe is maximally anteflexed, 
showing the long axis of the right ventricle and tricuspid valve (A–B). The model explains 
orientation of the imaging planes (C). 






























Figure 12. “Septal hugging” — clip path not perpendicular to the plain of the valve  
